{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:13:09Z","timestamp":1784041989223,"version":"3.55.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intern J of Cosmetic Sci"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Atopic dermatitis has a marked economic impact and affects the quality of life. A cosmetic compound with an innovative strategy is proposed here as a small chemical neutraligand, GPN279 (previously identified as a theophylline derivative), that binds and potently neutralizes the TARC\/CCL17 chemokine, activating the Th2 cell\u2010expressed CCR4 receptor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Our objective was to evaluate the safety and activity of topically applied GPN279 in mild\u2010to\u2010moderate atopic dermatitis patients in a randomized, double\u2010blind, placebo\u2010controlled, parallel group trial. Such cosmetic active ingredient targeting dry skin with an atopic tendency would open a parallel strategy to the pharmaceutical approach, in particular for mild to moderate subjects, as an alternative to reduce the evolution towards severe forms of atopy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This 4\u2010week trial included adults with mild\u2010to\u2010moderate atopic dermatitis, according to the SCORAD index. Patients were randomized into two groups treated by topical applications of either an emulsion containing 0.44% GPN279 in placebo on skin lesions or the placebo (4.56% glycerin). Clinical activity was evaluated with the SCORAD as the primary objective. As secondary objectives, POEM, erythema, skin moisturization, its barrier function (TEWL) and safety were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010one patients in each group completed the study. SCORAD was significantly improved in the GPN279 group vs. placebo. GPN279 also significantly improved POEM, induced a rapid and significant decrease of erythema, and improved skin moisture. GPN279 and placebo were well tolerated throughout the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A cosmetic cream comprising the CCL17 neutraligand GPN279 improved the skin barrier and physiology criteria in patients with mild\u2010to\u2010moderate atopic dermatitis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ics.12948","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T05:19:41Z","timestamp":1707369581000},"page":"468-477","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Randomized double\u2010blind placebo\u2010controlled cosmetic trial of a topical first\u2010in\u2010class Neutraligand targeting the chemokine <scp>TARC<\/scp>\/<scp>CCL17<\/scp> in mild\u2010to\u2010moderate atopic dermatitis"],"prefix":"10.1111","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-3755","authenticated-orcid":false,"given":"Nelly","family":"Frossard","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy UMR7200, LIT, CNRS\u2010Strasbourg University  Illkirch France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Co\u00efc","sequence":"additional","affiliation":[{"name":"GreenPharma SAS  Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-1773","authenticated-orcid":false,"given":"Thibaut","family":"Saguet","sequence":"additional","affiliation":[{"name":"TS Consulting  Olivet France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Co\u00efc","sequence":"additional","affiliation":[{"name":"GreenPharma SAS  Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Himbert","sequence":"additional","affiliation":[{"name":"GreenPharma SAS  Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc Tuan","family":"Do","sequence":"additional","affiliation":[{"name":"GreenPharma SAS  Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-3367","authenticated-orcid":false,"given":"Jean\u2010Luc","family":"Galzi","sequence":"additional","affiliation":[{"name":"UMR7242, CNRS\u2010Strasbourg University, ESBS  Illkirch France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-3496","authenticated-orcid":false,"given":"Carey","family":"Suehs","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases University Hospitals  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Guillaumet","sequence":"additional","affiliation":[{"name":"Institute of Organic and analytical chemistry Orleans University  Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-138X","authenticated-orcid":false,"given":"Pascal","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Institute of Organic and analytical chemistry Orleans University  Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4420-617X","authenticated-orcid":false,"given":"Philippe","family":"Bernard","sequence":"additional","affiliation":[{"name":"GreenPharma SAS  Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0287-7"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0151-9638(18)30088-7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000484407"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2023911"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.449348"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.12.003"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml200017d"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000487140"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00657"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903535867"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2005.11.001"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra074081"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0151-9638(20)31082-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.23.15036"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061392"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02095.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000198"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep14746"},{"key":"e_1_2_8_21_1","unstructured":"BernardP AbboudD GalziJ\u2010L FrossardN PillardC TuanQ.Dermocosmetic or pharmaceutical use of a composition comprising at least one inhibitor of some chemoattractant cytokines. 2016. Patent WO 2016\/046456."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000247298"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1513"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12590"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1265"},{"key":"e_1_2_8_26_1","volume-title":"R: a language and environment for statistical computing [Internet]","author":"R Core Team","year":"2021"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0906126107"},{"issue":"2","key":"e_1_2_8_28_1","first-page":"97","article-title":"Pathogenesis of atopic dermatitis: current paradigm","volume":"16","author":"Furue M","year":"2019","journal-title":"Iran J Immunol"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017520"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21027"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20873"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2494.2007.00364.x"},{"issue":"2","key":"e_1_2_8_34_1","article-title":"Emollients and moisturisers for eczema","volume":"2","author":"Zuuren EJ","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.95.08030347"},{"key":"e_1_2_8_36_1","unstructured":"AbboudD.Role of chemokines in atopic diseases. Pharmacological study using neutraligands. Thesis Strasbourg University2014Available from:https:\/\/www.theses.fr\/2014STRAJ023[Accessed September 24 2014]."},{"issue":"4","key":"e_1_2_8_37_1","first-page":"523","article-title":"Treatment options for atopic dermatitis","volume":"75","author":"Buys LM","year":"2007","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00404466"}],"container-title":["International Journal of Cosmetic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ics.12948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T04:34:30Z","timestamp":1717475670000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ics.12948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/ics.12948"],"URL":"https:\/\/doi.org\/10.1111\/ics.12948","archive":["Portico"],"relation":{},"ISSN":["0142-5463","1468-2494"],"issn-type":[{"value":"0142-5463","type":"print"},{"value":"1468-2494","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"2023-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}